Podcasts
Displaying 31–40 of 56
-
Eye on the Cure Podcast | Episode 57: James Rath
Eye on the CureJames Rath, a renowned filmmaker and accessibility consultant, talks to host Ben Shaberman about his vision loss journey and travel documentary, Blindspots. The new streaming program, on CuriosityStream.com, follows James as he explores the globe in search of accessible adventures, remarkable blind personalities, and great food.
-
Eye on the Cure Podcast | Episode 56: Michael Voevodsky, MBA, CEO
Eye on the CureMichael Voevodsky, MBA, CEO at MitoChem Therapeutics, talks to host Ben Shaberman about his company’s emerging, gene-agnostic treatment designed to boost mitochondrial function for preserving vision in people with retinitis pigmentosa, age-related macular degeneration, and other retinal conditions.
-
Eye on the Cure Podcast | Episode 55: Omar Mahroo, MB, PhD
Eye on the CureOmar Mahroo, MB, PhD, talks with host Ben Shaberman about electrophysiological testing for the retina, namely the electroretinogram (ERG), and its important role in evaluating and diagnosing inherited retinal diseases. Dr. Mahroo is a consultant ophthalmologist and retinal specialist at Moorfields Eye Hospital and St. Thomas’ Hospital in London, and Professor of Retinal Neuroscience at University College London.
-
Eye on the Cure Podcast | Episode 54: Rachelle Lin, OD, MS, FAAO
Eye on the CureRachelle Lin, OD, MS, FAAO, an optometrist and assistant professor at the Southern California College of Optometry at Marshall B. Ketchum University, talks with host Ben Shaberman about the critical role of optometrists in providing care and low-vision resources for patients with inherited retinal diseases and other eye conditions.
-
Eye on the Cure Podcast | Episode 53: David Birch, PhD
Eye on the CureDavid Birch, PhD, at the Retina Foundation of the Southwest in Dallas, talks to host Ben Shaberman about his productive and impactful 40-plus-year career as a retinal disease researcher and clinical trial investigator. Dr. Birch also discusses the challenges and opportunities for advancing more therapies through trials and out to the people who need them.
-
Eye on the Cure Podcast | Episode 52: Brendan Creemer
Eye on the CureSeptember 1, 2023. Brendan Creemer talks to host Ben Shaberman about how he is taking on the diagnosis of Usher syndrome 1F by dedicating his education and career to becoming a researcher for retinal disease treatments and cures.
-
Eye on the Cure Podcast | Episode 51: Artur Cideciyan, PhD
Eye on the CureAugust 18, 2023. Artur Cideciyan, PhD, one of the world’s foremost authorities in measuring vision and structural changes in people with retinal diseases, talks with host Ben Shaberman about current imaging tools, functional tests, and his experience as an investigator in several prominent clinical trials at the University of Pennsylvania, Scheie Eye Institute.
-
Eye on the Cure Podcast | Episode 50: Rachel Huckfeldt, MD, PhD
Eye on the CureJuly 21, 2023. Rachel Huckfeldt, MD, PhD, a clinical researcher and assistant professor of ophthalmology at Mass Eye and Ear, talks with host Ben Shaberman about caring for patients with inherited retinal diseases (IRD), the challenges and opportunities with clinical trials, and the educational and professional journey that led her to the IRD research field.
-
Eye on the Cure Podcast | Episode 49: Alex Cohen, PhD
Eye on the CureJune 30, 2023. Alex Cohen, PhD, a marketing professor with retinitis pigmentosa, talks with host Ben Shaberman about his career in the hospitality industry and launch of Accessible Pharmacy, a comprehensive pharmacy service for people with vision loss.
-
Eye on the Cure Podcast | Episode 48: Jami Kern, PhD
Eye on the CureJune 16, 2023. Jami Kern, PhD, chief clinical officer at Nacuity Pharmaceuticals, talks with host Ben Shaberman about NACA, the company’s emerging gene-agnostic therapy for Usher syndrome and retinitis pigmentosa in a Phase 2 clinical trial in Australia. Their conversation includes a discussion about oxidative stress, which NACA is designed to mitigate, and timing for the efficacy readout from the Phase 2 study.
%20(14).png)
%20(13).png)
%20(12).png)
%20(11).png)
.png)
%20(10).png)
%20(9).png)
%20(8).png)
%20(7).png)
